GERMANY MEDTECH PITCH DECK AGENCY
MedTech Pitch Deck Design Agency Germany That Clears EU MDR and Raises Capital
Where German Device Innovation Meets European Investment Capital
Germany is Europe's largest medical device market, with roughly €17 billion in annual domestic sales and over 14,000 companies including Siemens Healthineers, Fresenius, B. Braun Melsungen, Drägerwerk, and Carl Zeiss Meditec. EU MDR 2017/745, the biggest European medical device overhaul in three decades, is disrupting legacy device makers while opening commercial space for startups built to the new standard from day one, tracked by BioM Venture Capital, Bayern Kapital, and HTGF.
German medtech capital splits into two audiences with conflicting requirements. Financial VCs like BioM and Bayern Kapital evaluate market size, MDR certification timeline, and GKV reimbursability. Strategic corporates like Siemens Healthineers Ventures and Bosch Health Campus evaluate portfolio fit, existing hospital procurement access, and whether clinical evidence meets their customers' adoption bar. A deck built for VC scalability fails corporate integration questions, and one built for corporate depth overwhelms VCs assessing initial market size.
Slidey is the MedTech pitch deck design agency Germany founders rely on to satisfy both financial VC commercial expectations and strategic corporate integration criteria within one coherent investment story.
Two Regulatory Forces Shaping German MedTech Investment Right Now
MDR 2017/745 recertification demands are pricing out Mittelstand manufacturers who held MDD certification, opening space investors are actively funding. Our MedTech startup pitch deck consultants Germany team positions this MDD-to-MDR disruption as a market timing slide showing exactly which position is available.
Without G-BA reimbursement, a device reaches only the 10 percent PKV-insured population. NUB status unlocks GKV's 90 percent coverage, and Slidey positions the NUB pathway timeline as the true commercial revenue milestone investors need to see.
GERMAN MEDTECH DECKS NEED TO PASS TWO COMPLETELY DIFFERENT TESTS
Our MedTech pitch deck design service Germany team shows which product line your device extends, which hospital relationships accelerate adoption, and whether your data fits Siemens Healthineers' existing clinical workflows.
Siemens, Bosch, Zeiss, and B. Braun built a national quality signal that shapes hospital purchasing decisions in Asia, the Middle East, and the US. Slidey positions "Made in Germany" as global expansion leverage, not a domestic footnote.
The Evidence Hierarchy German MedTech Investors Apply
BioM Venture Capital, Bayern Kapital, HTGF, and strategic corporates rank evidence in a specific order. EU MDR conformity status comes first, with new MDR CE marking ranking above old MDD marking. G-BA NUB status or existing DRG reimbursement ranks second because GKV coverage unlocks 90 percent of German market revenue. Clinical evidence quality ranks third, with peer-reviewed data from Charité Berlin, LMU Munich, or Heidelberg University Hospital outweighing single-site pilots. German manufacturing or development partnerships with Siemens Healthineers, B. Braun, or Dräger rank fourth, signaling quality and hospital access together. Our MedTech pitch deck experts Germany team presents each level explicitly, in the sequence investors actually apply it. Results below are actual raises.
.avif)
Raised
.avif)
Raised
.avif)
Raised
.avif)
Raised
Building a German MedTech Deck Step by Step
German MedTech Discovery
We identify device class, MDR status, NUB pathway, and investor audience.
EU MDR Clinical Evidence Architecture
We structure the literature review, investigation plan, and follow-up framework
.svg)
GKV Reimbursement Pathway Slide
We map NUB submission, DRG coding, and first reimbursement revenue timing.
.svg)
University Hospital Clinical Validation Network
We position Charité, LMU, and Heidelberg partnerships as credibility evidence.
.svg)
DiGA Approval Architecture
We build the BfArM fast-track and GKV prescription reimbursement pathway slide.
.svg)
Multi-Audience German Delivery Package
We prepare the investor deck, clinical dossier, regulatory summary, and hospital presentation.
German MedTech Precision Extends to Our Pricing Too
Built for early-stage German medtech raising seed rounds from HTGF, BioM, or Bayern Kapital with EU MDR submission in preparation or notified body review underway.
$800
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
Every German MedTech Raise Has a Different Starting Point
German MedTech Decks That Passed the Toughest Clinical Investor Scrutiny
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.avif)
.svg)